Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Anthera sees 64% of its value wiped off as CF candidate flunks phase 3 test
Anthera sees 64% of its value wiped off as CF candidate flunks phase 3 test
Anthera sees 64% of its value wiped off as CF candidate flunks phase 3 test
Submitted by
admin
on December 28, 2016 - 7:34pm
Source:
Fierce Biotech
News Tags:
Anthera
clinical trials
cystic fibrosis
Sollpura
Headline:
Anthera sees 64% of its value wiped off as CF candidate flunks phase 3 test
Do Not Allow Advertisers to Use My Personal information
